\n\n\n\n\t\t\n\t\t\tHistoRx\n\t\t\thttp://www.historx.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tHistoRx offers the first advanced histopathology analysis platform, using the company\u2019s proprietary AQUA\xae technology capable of measuring biomarker concentration with sub-cellular resolution in tissue...More»
\n\t\t\tHistoRx offers the first advanced histopathology analysis platform, using the company\u2019s proprietary AQUA\xae technology capable of measuring biomarker concentration with sub-cellular resolution in tissue sections. HistoRx services are used throughout basic biomedical research, preclinical and clinical drug development studies, facilitating the efforts of pharmaceutical and biotechnology companies to improve efficiency and effectiveness throughout drug development to bring new targeted therapies to the market. HistoRx pursues internal programs to develop proprietary standard-of-care diagnostics that offer substantial improvements over existing immunohistochemistry-based tests. HistoRx provides academic researchers at leading institutions access to AQUA\xae technology for use exclusively in noncommercial research.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tNew Haven, CT, United States\n
\n\t\t\t\tIndustry: Medical Devices & Equipment
\n\t\t\t\tEmployees: 27
\n\t\t\t\tTags:\n\t\t\t\tdrug development,\n\t\t\t\tbiomarker,\n\t\t\t\ttissue,\n\t\t\t\tCellular,\n\t\t\t\ttissue biomarker,\n\t\t\t\timage,\n\t\t\t\tdiagnostics,\n\t\t\t\ttissue analysis,\n\t\t\t\tsoftware\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series B - $6M (10/24/2007)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tBrook Venture Partners, Navigator Technology Ventures, The Roche Venture Fund, Commons Capital, Maven Capital\n\t\t\t\t
\n\t\t\tMarket
\n\t\t\t\tCompetitors:\n\t\t\t\t\t\tOryzon Genomics\n\t\t\t\t
\n\n\t\t\t\tRelated Companies:\n\t\t\t\t\tComplete Genomics\n\t\t\t\t
\n\t\t\t